Author:
Schwartzmann Benjamin,Quilty Lena C.,Dhami Prabhjot,Uher Rudolf,Allen Timothy A.,Kloiber Stefan,Lam Raymond W.,Frey Benicio N.,Milev Roumen,Müller Daniel J.,Soares Claudio N.,Foster Jane A.,Rotzinger Susan,Kennedy Sidney H.,Farzan Faranak
Abstract
AbstractCognitive behavioral therapy (CBT) is often recommended as a first-line treatment in depression. However, access to CBT remains limited, and up to 50% of patients do not benefit from this therapy. Identifying biomarkers that can predict which patients will respond to CBT may assist in designing optimal treatment allocation strategies. In a Canadian Biomarker Integration Network for Depression (CAN-BIND) study, forty-one adults with depression were recruited to undergo a 16-week course of CBT with thirty having resting-state electroencephalography (EEG) recorded at baseline and week 2 of therapy. Successful clinical response to CBT was defined as a 50% or greater reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to post-treatment completion. EEG relative power spectral measures were analyzed at baseline, week 2, and as early changes from baseline to week 2. At baseline, lower relative delta (0.5–4 Hz) power was observed in responders. This difference was predictive of successful clinical response to CBT. Furthermore, responders exhibited an early increase in relative delta power and a decrease in relative alpha (8–12 Hz) power compared to non-responders. These changes were also found to be good predictors of response to the therapy. These findings showed the potential utility of resting-state EEG in predicting CBT outcomes. They also further reinforce the promise of an EEG-based clinical decision-making tool to support treatment decisions for each patient.
Publisher
Springer Science and Business Media LLC
Reference98 articles.
1. James, S. L. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789–1858 (2018).
2. World Health Organization. Depression and other common mental disorders global health estimates (2017).
3. World Health Organization. Depression. https://www.who.int/news-room/fact-sheets/detail/depression (2018).
4. Gelenberg, A. J. et al. Practice guideline for the treatment of patients with major depressive disorder third edition work group on major depressive disorder (2010).
5. Kennedy, S., Lam, R., Cohen, N. & Ravindran, A. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can. J. Psychiatry 46(Suppl 1), 38S-58S (2001).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献